oronary artery disease still represents the leading cause of mortality and morbidity in the developed world. Percutaneous coronary intervention (PCI) took its first steps in 1964 when Charles Theodore Dotter and Melvin P. Judkins described the first angioplasty; 13 years later, Andreas Grüntzig performed the first balloon coronary angioplasty, a revolutionary treatment that led to the birth of a new specialty, interventional cardiology. To date, coronary stents, which were first developed in the mid-1980s, have ultimately replaced "plain old balloon angioplasty (POBA)" as the preferred method of performing PCI, after the observed improvements in angiographic and clinical outcomes seen with their use, hence representing the most common major medical intervention in catheterization laboratories worldwide. 1 The majority of PCI procedures nowadays involve a coronary stent, and interventional cardiologists are faced with a wide choice of coronary stents to implant, such as bare metal stents (BMS) and drug-eluting stents (DES). Coronary stenting only became a widely accepted technique after the publication in 1994 of the landmark BENESTENT trial and the STRESS study, together with evidence indicating that stenting was safe in the absence of anticoagulation therapy with the use of dual antiplatelet therapy and/or adequate stent deployment. 2 In spite of some relevant strong points such as greater than 90% success rate and the repeatability of the procedure, several major drawbacks still persist, including restenosis within the treated vessel. 3 The latter phenomenon is currently the object of intensive research in different areas that are considering stents capable of being either biodegradable or self-expanding or polymer-free or coated with newer agents. 4 Therefore, the aims of this review article are to evaluate the state-of-the-art data on vascular smooth muscle cell (VSMC) proliferation in the restenosis phenomenon, together with therapeutic options and the role of endothelium on neointimal hyperplasia (NIH) and stent thrombosis.
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CURCIO A et al. Figure 2 . Physiopathological mechanisms of restenosis after experimental balloon injuries. Representative histological crosssections. Common carotid artery from (A) normal rat (no balloon injury), (B) after injury with a 2Fr Fogarty balloon, (C) after injury using the angioplasty balloon catheter and (D) 28 days after injury using the angioplasty balloon catheter. Balloon injury with the 2Fr Fogarty caused a homogeneous formation of neointima with no rupture of the internal elastic lamina (IEL) (B). In contrast, using the angioplasty balloon catheter, neointimal formation was negligible when the IEL was intact (C). Eccentric neointimal lesions were observed where the IEL was lacerated (D, arrows). Top, Van Gieson ×100; Middle, hematoxylin-eosin ×400; Bottom, schematic drawings ×400. (Modified from Indolfi C et al. 9 ) Figure 1 . Adverse negative vessel remodeling induced by percutaneous transluminal coronary angioplasty (PTCA) and stenting. Following PTCA, stretch-induced vessel recoil is associated with activation of vascular smooth muscle cell (VSMC) proliferation. On the other hand, VSMC proliferation from the tunica media toward intima is the sole determinant of restenosis after stent deployment. VSMC and Endothelial Regeneration After Stenting caused primarily by the effects of VSMC proliferation and migration (Figure 1 ). 5 Cell proliferation after stenting occurs both early, as part of the acute injury response, and late, located around stent struts. Whereas some neointima formation is necessary for vessel healing after stenting, to bury the stent struts within the vessel wall and to prevent exposure to the flowing blood, excessive neointima formation narrows the lumen. 6 The endothelium plays a central role in maintaining vascular health by virtue of the endothelial cells' (ECs) antiinflammatory and anticoagulant properties. 7 It has been demonstrated that in a rat model of carotid artery dilation by percutaneous transluminal coronary angioplasty (PTCA) balloon catheter, the first step in allowing VSMC proliferation from the tunica media to the intima is the occurrence of internal elastic lamina (IEL) rupture (Figure 2 ). 8, 9 In that study, VSMC proliferation was tightly correlated with rupture of the IEL, which occurs in about 40% of the experimental PTCA performed to trigger VSMC proliferation. Remarkably, when the IEL was intact after POBA, neointimal formation was negligible. 9 An additional finding was that for the first time negative remodeling after balloon dilation with a PTCA catheter was demonstrated in rat arteries. It should be also pointed out that in the Fogarty model of the rat carotid artery experimental angioplasty, VSMC proliferation, which occurs in 100% of the cases, is proportional to the extent of balloon injury. 10 This issue has been demonstrated at both the histological and molecular level. In fact, after inserting a 2F Fogarty catheter into the lumen of a rat common carotid artery, before passing it back and forth 3 times inside the vessel, different inflation pressures of 0 (passing only the deflated balloon three times), 0.5, 1.0, 1.5, and 2.0 ATM were applied. 10 Remarkably, analyzing cross-sections from the carotid arteries after progressive vascular injury, it was assessed for the first time that the proliferative response of VSMC was proportional to the degree of vascular injury, and these findings were confirmed from RNA extraction at 30 min after the balloon injury, demonstrating that increasing the inflation pressure proportionally stimulates c-fos expression and drives neointimal formation and proliferation. 10 In this regard, other small animal models that may resemble the effects of human vascular injury after interventional procedures could be of great interest for studying the restenosis phenomenon and for assessing potential therapeutic strategies. 11 In fact, we described a new model of arterial stenting in the rat, showing that in this animal model (1) at day 7 significant neointima and an organizing fibrin thrombus were present around the stent wires; (2) neointima formation and the neointima -media ratio increased significantly at 14 days; Figure 3 . A new rat model of small vessel stenting. Photomicrographs of plastic-embedded sections 0, 7, 14, 21, 28, days after stent deployment. At 30 min after stent placement, the carotid arteries showed thinning of the media with area of medial compression. After 7 days, a significant neointima and an organizing fibrin thrombus were present around the stent wires. The neointima formation and the neointima -media ratio increased significantly at 14 days. At 21 and 28 days the neointima and the neointima -media ratio were not statistically increased compared with the results obtained at 14 days after stent deployment. (3) at 21 and 28 days the neointima and the neointima -media ratio were not statistically increased compared with the results obtained at 14 days after stent deployment; (4) no significant differences in the area of external elastic lamina were observed during the study period (from 0 to 28 days), whereas the internal lumen area was reduced significantly at 14 days after the stent deployment (Figure 3 ). 11 
Restenosis in Diabetes and the Elderly
The possibility of investigating cellular proliferation in the vessels prompted us to address experimental projects for unraveling the molecular mechanisms that underlie the "exaggerated" vascular proliferation seen in patients affected by diabetes mellitus and, accordingly, the relative role of hyperglycemia vs. hyperinsulinemia in promoting greater restenosis after angioplasty or stenting under such pathological conditions (Figure 4 ). 12 In order to assess this topic, we analyzed for the first time the effect of balloon injury on NIH in streptozotocin-induced diabetic rats with and without adjunct insulin therapy. In addition, to study the effect of balloon injury in nondiabetic rats with hyperinsulinemia, pancreatic islets were transplanted under the kidney capsule in normal rats. 13 First, we demonstrated that glucose did not increase VSMC proliferation and migration in vitro. In contrast, insulin induced a significant increase in VSMC proliferation and migration in the cell cultures. Furthermore, in cultured VSMCs, insulin increased MAPK activation. 13 Surprisingly, a reduction in NIH was documented consistently after vascular injury in hyperglycemic streptozotocin-induced diabetic rats in vivo, whereas insulin therapy significantly increased NIH in these rats. Interestingly, after experimental balloon angioplasty in hyperinsulinemic nondiabetic islet-transplanted rats, a significant increase in NIH was also observed. 13 Therefore, hyperinsulinemia through activation of the ras -MAPK pathway, rather than hyperglycemia per se, appears to be crucial in determining the exaggerated neointimal response after balloon angioplasty in diabetic animals. This point has recently become crucial in the clinical scenario, since diabetes is one of the main problems of percutaneous coronary revascularization, representing the actual dark side of in-stent restenosis. 14 Moreover, catheterization procedures are oftentimes performed in elderly patients with coronary artery disease. 15 For quite a long time, the elderly have been considered a procedural risk for PCI. However, the stent era seems to have improved the outcome of PCI in aged patients. This preliminary finding could correlate with decreased VSMC proliferation after stent deployment (which is actually the main factor determining restenosis after stenting) in elderly patients. To dissect this issue, we performed experimental angioplasty in the common carotid artery of old rats (age >24 months). 16 In that study, we demonstrated decreased VSMC proliferation in aged animals, due to Akt suppression and an increase in the vascular apoptosis rate, together with strikingly reduced re-endothelialization after balloon injury, due to reduced total and phosphorylated levels of endothelial nitric oxide synthase (eNOS). 16 The latter in turn could determine an increased risk for thrombotic complications in aged patients after PCI, especially when using DES that also inhibit endothelial growth. Therefore, this study underlines Representative hematoxylin-eosin -stained histological sections of common carotid arteries after balloon injury from each group of animals studied: rats subjected to only balloon injury (CON), rats treated with streptozotocin (STZ), insulin-treated STZ-induced diabetic rats (STZ + INS), hyperinsulinemic nondiabetic islet-transplanted rats (Transp Hyperins), and insulin-treated rats with STZ-induced diabetes with transfection of ras-negative mutant gene (STZ + INS/ras -). (Modified from Indolfi C et al. 13 ) VSMC and Endothelial Regeneration After Stenting the importance of aggressive medical therapy for old patients after stent deployment targeted to reducing thrombotic events, and increasing endothelial survival and proliferation more than just dealing with VSMC proliferation.
VSMC Intracellular Signaling After Vascular Injury
In the past decade, we sought to target at the molecular level both MAPK and cAMP -protein kinase A (PKA) signaling pathways in order to inhibit neointima formation after balloon injury (Figure 5 ). [17] [18] [19] [20] [21] Ras proteins are key transducers of mitogenic signals from the plasma membrane to the nucleus in many cell types. We investigated the role of ras proteins in the vascular response to arterial injury in vivo by inactivating cellular ras function in balloon-injured rats. 17 In animals treated with N17 H ras, a mutant of ras acting in a dominant negative manner to block normal ras activation, a significant reduction of neointima formation (-55%) was observed 14 days after balloon injury compared with animals treated with RSV-lacZ. A similar effect on neointima formation after vascular injury was observed with inhibition of MAPKK by a dominant inhibitor mutant gene. 18 To investigate the effects of cAMP/PKA signaling on VSMC proliferation, we evaluated in vitro cultures with different concentrations of 8-Br-cAMP and analyzed cell growth at different treatment periods. 19 cAMP/PKA activation markedly inhibited VSMC proliferation. We next sought to determine whether cAMP/PKA signaling was able to inhibit VSMC proliferation in vivo by balloon-injuring rat carotid arteries. At the time of balloon injury, we locally delivered 8-Br-cAMP on the carotid arteries by using pluronic gel. In the 8-Br-cAMP group, a significant reduction of neointima (-54%) was observed 14 days after vascular injury compared with the control group. 19 Inhibition of neointimal formation after vascular injury also was observed in other experiments, in which systemic administration of 8-Cl-cAMP reduced PKA RIα subunit expression and upregulated PKA RIIβ-subunit expression. 20 In this regard, in an attempt to amplify and stimulate at molecular level the pathway of cAMP/PKA, we overexpressed the A kinase anchor protein that binds and anchors the regulatory subunit of PKA to the subcellular membranes (AKAP75) in cultured VSMCs in vitro and in arteries subjected to balloon injury, resulting in activation of cAMP-induced transcription, increased levels of p27kip1, Figure 5 . Molecular mechanisms of vascular smooth muscle cell proliferation and selected intracellular targets for antiproliferative strategies. Once activated, the tyrosine kinase receptor triggers a cascade of tyrosine phosphorylations, which lead to the formation of a ternary complex connecting the receptor to ras. Active ras binds the serine protein kinase raf [even named MEKK or MAPKKK (mitogen-activated protein kinase kinase kinase)], which activates MAPKK/MEK (mitogen-activated protein kinase kinase). This cascade culminates in the activation of the nuclear transcription factors. On the other side of the figure, the 7-transmembrane spanning receptor, upon binding the hormone, activates the heterotrimeric G-protein cascade. Gαs (GTP bound) activates adenylate cyclase (AC), which increases cyclic adenosine monophosphate (cAMP) production. cAMP binds the tetrameric enzyme protein kinase A (PKA) and dissociates the enzyme by releasing the active catalytic subunit (C), which phosphorylates several substrates in the cytoplasm, including raf. A fraction of C migrates to the nucleus where it stimulates the transcription of several cAMP-responsive genes, leading to the suppression or stimulation of cellular growth. CURCIO A et al. and suppression of both VSMC growth in vitro and NIH after balloon injury. 21 These in vitro and in vivo effects were dependent on selective stimulation of the AKAP-targeted PKA RIIβ-subunit, since a PKA-specific inhibitor, PKI, but not its inactive mutant, was able to inhibit the effects of AKAP both in vivo and in vitro. 21 That study showed once more that blocking or amplifying intracellular pathways that favor or inhibit, respectively, VSMC proliferation and migration represent feasible strategies that should be pursued in order to identify the ideal strategy for preventing the restenosis phenomenon.
DES in the Clinical Scenario
Pioneering experimental and clinical data from the end of the last millennium have clearly demonstrated that after balloon angioplasty VSMC proliferation plays a pivotal role in causing restenosis of the treated vessel and that constrictive remodeling, elastic recoil and the neointimal hyperplastic healing response together could be prevented by coronary stenting technology, which in turn provided a solution to acute vessel reocclusion by sealing the dissection flaps and preventing recoil, hence representing the "second revolution" in interventional cardiology. After BMS implantation restenosis rates were 20-30%, so additional advancements toward a strategy for curing in-stent restenosis eventually led to the concept of delivering selective antiproliferative drugs at the site of neointima formation. Therefore, DES were introduced into the clinical setting, representing the so-called "third revolution" in interventional cardiology. The first human DES implant was performed by J Eduardo Sousa in Sao Paulo in December 1999, using a Cypher SES (sirolimus-eluting stent). 22, 23 The TAXUS PES (paclitaxel-eluting stent) was developed almost simultaneously with the SES, gaining regulatory approval 12 months later. 24, 25 The outstanding results from the early pivotal trials with DES were subsequently reinforced by several meta-analyses from our laboratory and others, demonstrating that DES produced significant decreases in the need for percutaneous revascularization such that their use has expanded to lesions subsets that were only previously considered suitable for coronary artery bypass grafting as opposed to BMS. 1,26 This increased confidence led to a rapid and unprecedented uptake in their use, so that by 2005, 80-90% of all revascularization procedures in the US were performed using a DES, which were believed to confer dramatic reductions in both clinical restenosis and the need for target lesion revascularization over prior BMS counterparts. 27-29 Initial enthusiasm, however, has been tempered by growing concerns surrounding the risks of late stent thrombosis. In his address to the 2006 European Society of Cardiology congress, Camenzind reported a significantly higher 6.3% combined death/myocardial infarction rate of DES over the 3.9% Figure 6 . In vitro experiments of vascular smooth muscle cells (VSMCs) incubated with methacrylate-coated stents. Methacrylate (MA) films were applied in a liquid state on 13 mg, 8-mm long, stainless steel stents. Sterilization was carried out with ethylene oxide gas. VSMCs were obtained from male Wistar rats. After isolation and collection, 1×10 5 VSMCs were plated in DMEM with 10% FCS until reaching 70-90% confluence. A MA-coated stent (0.3, 1.5 or 3 ml) or an uncoated stent was gently added to each well, and other cells were grown without any stent. It is impressive that MA-coated stents induced dose-dependent VSMC apoptosis detected by fluorescence microscopy with propidium iodide. (Modified from Curcio A et al. 34 ) VSMC and Endothelial Regeneration After Stenting observed for BMS. 30 This announcement raised brewing concerns followed by additional isolated reports of DES thrombosis. 31 The pathophysiology of stent thrombosis has not been fully elucidated. A combination of factors might be involved, including procedure-related variables, patientrelated issues, and lesion characteristics. In a prospective observational study, premature clopidogrel discontinuation predicted the risk of thrombosis. 32 Remarkably, several concerns have also been raised about the polymer coatings that facilitate drug release from the stent struts but remain long after drug elution is complete. These permanent polymers can cause delayed healing, impaired endothelialization, and a hypersensitivity reaction, which can culminate in stent thrombosis. 33 Ex vivo data from histopathological studies, as well as in vitro experiments, also indicate that these non-erodable polymers, such as methacrylate, can precipitate stent thrombosis by inducing localized vascular inflammation, hypereosinophilia, thrombogenic reactions, and apoptosis of VSMCs (Figure 6) . 34 Therefore, the concept was refined that the ideal DES should exert simultaneous antiproliferative and antiinflammatory properties. To this end, in our laboratory we coated stainless steel stents with 0.2 ml/cm of polymethacry-late polymer, followed by dissolution of fludarabine 1.5 mg to create the fludarabine-eluting stent (FES). 35 Fludarabine is a purine analog used for curing hematological malignancies since it exerts its immunosuppressive activity through the inhibition of STAT-1 signaling, hence representing a valid alternative to rapamycin and paclitaxel. Experimental stenting in the rabbit common carotid artery treated with FES implantation displayed a significant reduction in both NIH (2±0.6 mm 2 vs. 5.3±0.5 mm 2 ) and the neointima -media ratio (0.9±0.3 vs. 2.0±0.02) compared with BMS. 35 This reduction in VSMC proliferation was associated with a significant prevention of STAT-1 phosphorylation at 2 and 7 days and fludarabine also inhibited JAK2-increased expression at 7 days.
Effect of Endothelial Regeneration and VSMC Proliferation on Restenosis: Possible Therapeutic Strategies
Both SES and PES have been associated with significant endothelium-dependent vasomotor dysfunction assessed at coronary vasomotion studies. 36-42 Nitric oxide (NO) is a key factor generated by eNOS, and is associated with inhibition of platelet and leukocyte activation, and maintenance of vascular smooth muscle in a nonproliferative state. In addition to being the main determinant of basal vascular smooth muscle tone, NO opposes the actions of potent endotheliumderived contracting factors such as angiotensin-II and endothelin-1. Impairment of NO bioactivity or bioavailability and/or imbalance between endothelium-derived relaxing and contracting factors is crucial in the mechanisms of endothelial dysfunction. Exercise training has assumed a major role in both the primary and secondary prevention of coronary artery disease, the benefits of which are mostly related to the increased bioavailability of NO in the arteries of trained subjects. In particular, it has been reported that exercise increases eNOS expression and activity in the vascular wall. 43 Based on the beneficial effects of physical training, we started from the assumption that a regenerated endothelium showing normal morphological characteristics and functions may favorably affect restenosis and therefore sought to assess the feasibility of swimming exercise after balloon angioplasty and experimental stenting in the rat. 43 Histological assessments demonstrated that a regular daily training program achieved complete re-endothelialization of injured vessels and abolished neointima formation after both balloon angioplasty and stenting with increased eNOS activity, increased numbers of ECs measured by CD31 levels (Figure 7) and reduced platelet aggregation associated with enhanced carotid blood flow velocity after stenting. 43 As extensive efforts have been directed to investigating the best candidate drug associated with the optimal polymer, it has been argued that the potential of the first-generation DES to cause coronary thrombosis was perhaps attributable to their permanent polymer, hence leading to panoptic research into development of new polymers. 44 Several technical and bioengineered contributions have led to the second-generation DES with more biocompatible non-erodable polymers, which have been shown in animal studies to induce a greater degree of re-endothelialization compared with first-generation stents. [45] [46] [47] In particular, to prevent incomplete re-endothelialization after DES deployment, it has been suggested that DES should ideally have a selective antiproliferative effect on VSMCs, but be inert toward ECs or, better still, promote their proliferation. The latter could be achieved by the identification of drugs/intracellular molecules that play differential roles in VSMC and EC growth. Our experimental contribution to understanding the molecular and cellular determinants of smooth muscle and endothelium in restenosis and NIH comes from vascular gene transfer of dominant negative mutants of the regulatory subunit of the phosphatidylinositol 3-kinase, namely p85. 48 Indeed, we recently investigated the effects of overexpression of p85α PI3K plasmids in rat carotid arteries subjected to balloon injury, by using pluronic F127 gel as the sustained-release polymer. In this way, rat carotid arteries were locally transfected with FLAG tagged plasmid vectors expressing p85 WT , p85 PKA-inactive , and p85 PKA-activated immediately after balloon injury. 48 In this elegant experiment, we demonstrated that local delivery of p85 PKA-activated prevents VSMC proliferation and NIH after experimental balloon injury, and that p85 PKA-activated local delivery does not affect endothelial regeneration in rat balloon-injured arteries.
Conclusions and Future Perspectives
Aggressive VSMC proliferation has been considered for a long time to be the "Achille's heel" of PCI. Experimental studies have demonstrated in several models that negative vessel remodeling after POBA has a relevant impact on restenosis in addition to NIH. With the advent of coronary stenting VSMC proliferation was shown to be solely responsible for in-stent restenosis, but the use of DES has dramatically reduced coronary restenosis to less than 10% in several randomized trials. On the other hand another problem, late stent thrombosis, accompanied DES use, due to the fact that the structure and function of the endothelium remains abnormal after DES deployment. To date, no DES that solely block VSMC proliferation and favor endothelium regeneration are available. The so-called second generation DES (everolimus and zotarolimus stents) have been introduced to the clinical practice with some advantages over SES and PES. Additionally, new biocompatible polymers provided the trigger for the development of stents that provide only a temporary scaffold, namely biodegradable stents (Figure 8) , but in contrast to the vast amount of experimental data from large animal models, still few patients have been so far included in study groups to test the effective superiority of this promising technology. 49 Brand new therapeutic targets in proliferative vascular diseases might come in the near future from the study of microRNA, a novel class of endogenous, small, noncoding RNAs that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs. Their role in VSMC proliferation and in endothelium turnover has not been completely elucidated, and accordingly additional studies are warranted for establishing a new therapeutic approach for NIH and restenosis after DES.
